They observed that in the majority of SSc fibroblasts basal expression of Endoglin, pSMAD1, pSMAD3, CCN2, collagen type I was already elevated and was reduced after treatment with siENG, while in normal fibroblasts this treatment did not lead to significant changes other than in Endoglin, as expected. The gene discussed is CCN2; the disease is systemic sclerosis.